Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McGuire, D. K
Right arrow Articles by Ferrannini, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, D. K
Right arrow Articles by Ferrannini, E.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Diabetes
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

Darren K McGuire

Department of Internal Medicine, the University of Texas Southwestern Medical Center at Dallas, US.

Jeffrey R Winterfield

Brigham and Women's Hospital, Boston US.

Jason A Rytlewski

Department of Internal Medicine, the University of Texas Southwestern Medical Center at Dallas, US.

Ele Ferrannini

Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa School of Medicine, Pisa, Italy.

Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin-aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

Key Words: angiotensin-converting enzyme (ACE) inhibitor • angiotensin receptor blocker (ARB) • diabetes • prevention • renin-angiotensin-aldosterone system

Diabetes and Vascular Disease Research, Vol. 5, No. 1, 59-66 (2008)
DOI: 10.3132/dvdr.2008.011
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
G.-X. Zhang, S. Kimura, K. Murao, J. Shimizu, H. Matsuyoshi, and M. Takaki
Role of neuronal NO synthase in regulating vascular superoxide levels and mitogen-activated protein kinase phosphorylation
Cardiovasc Res, February 1, 2009; 81(2): 389 - 399.
[Abstract] [Full Text] [PDF]